---
layout: default
title: Toremifene
parent: 僅模型預測 (L5)
nav_order: 365
evidence_level: L5
indication_count: 1
---

# Toremifene
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Toremifene: From Breast Cancer (SERM) to HIV Infectious Disease

## One-Sentence Summary

Toremifene is a selective estrogen receptor modulator (SERM); literature context in the evidence pack identifies it as related to breast cancer treatment (mentioned alongside tamoxifen), though this original indication is not formally documented in the current dataset.
The TxGNN model predicts it may be effective for **HIV infectious disease**, but this is currently supported by only **1 in vitro/mechanistic publication** and **no clinical trials**, with the single reference actually studying anti-cryptococcal (not anti-HIV) activity.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in evidence pack (no Norway license data; drug not marketed) — literature context refers to toremifene as a breast cancer drug (SERM class) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 |
| Norway Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (`original_moa: [Data Gap]`). Based on the single literature reference in this evidence pack, toremifene is described as an estrogen receptor antagonist related to the breast cancer drug tamoxifen, and was found to have direct anti-cryptococcal activity in vitro by binding EF-hand proteins (e.g., calmodulin), synergizing with fluconazole and amphotericin B.

The link to "HIV infectious disease" is indirect: cryptococcal meningitis is a common opportunistic infection in HIV/AIDS patients, so the connection is at best "adjunct treatment for an HIV-associated opportunistic infection," not a direct antiviral mechanism against HIV itself. The TxGNN-predicted disease label (HIV infectious disease) and the underlying evidence (anti-cryptococcal, in vitro) are conceptually mismatched — this should be treated as a hypothesis-generating signal only, not a validated repurposing pathway.

Given the absence of any HIV-specific pharmacology, clinical trial, or in vivo data, the mechanistic plausibility is weak and unconfirmed at this stage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [24520056](https://pubmed.ncbi.nlm.nih.gov/24520056/) | 2014 | Basic/Mechanistic (in vitro; not an HIV study) | mBio | Estrogen receptor antagonists tamoxifen and toremifene show fungicidal, anti-cryptococcal activity in vitro and synergize with fluconazole/amphotericin B, mediated via direct binding to EF-hand proteins (e.g., calmodulin) |

---

## Norway Market Information

Toremifene is not currently marketed in Norway; no product authorization records are available in this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and DDI data are marked as Data Gap / not found in the current evidence pack, including a Blocking-severity gap on TFDA label warnings/contraindications — DG001.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The only supporting evidence is a single in vitro/mechanistic publication studying anti-cryptococcal activity, not HIV itself, with no clinical trials and a conceptual mismatch between the predicted disease label and the underlying mechanism. Combined with the drug's unmarketed status in Norway and missing MOA/safety data, the evidence is insufficient to move beyond preliminary screening (S0).

**To proceed, the following is needed:**
- TFDA/Norway label warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- Clarification of whether the intended use case is "treatment of HIV-associated opportunistic infection (cryptococcosis)" rather than direct anti-HIV therapy, and re-scoping the indication label accordingly
- In vivo or HIV/opportunistic-infection-specific pharmacological evidence before advancing past S0
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

